Gilead Sciences, Inc. is a large-cap biopharmaceutical company with a market cap of $139.9 billion. Despite trading below its 10-year high, GILD stock has seen a 22.3% YTD increase and 41.8% surge over the past year, outperforming the Nasdaq Composite. The company’s Q2 results exceeded expectations, driving an 8.3% stock surge. Analysts rate GILD as a “Strong Buy” with a mean price target of $126.33, indicating an 11.8% upside potential.

Read more at Yahoo Finance: Is Gilead Sciences Stock Underperforming the Nasdaq?